Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apovir (pleconaril + ribavirin) in Amyotrophic Lateral Sclerosis
2012-002099-15Phase 2Terminated
- Sponsor
- Apodemus AB
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Apovir (pleconaril + ribavirin) with Placebo (2 arms). Primary endpoint: Primary Safety Endpoint. Started Aug 2014; status: terminated.
02
Drugs
Apovir
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2012-002099-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002099-15.